Related Experiment Videos
Diarylsulfonamides as selective, non-peptidic thrombin inhibitors
I R Weber1, R Neidlein, W von der Saal
1Pharmazeutisch-Chemisches Institut der Universität, Heidelberg, Germany.
Bioorganic & Medicinal Chemistry Letters
|January 5, 1999
Summary
Researchers developed novel guanidinoalkyl-substituted diarylsulfonamides as potent thrombin inhibitors. The lead compound selectively inhibited thrombin, with structural analysis revealing key binding interactions for drug design.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Structural Biology
Background:
- Thrombin is a key enzyme in blood coagulation.
- Developing selective thrombin inhibitors is crucial for anticoagulant therapy.
- Aminopyridine derivatives serve as a structural basis for novel inhibitors.
Purpose of the Study:
- To synthesize and evaluate novel aminoalkyl- and guanidinoalkyl-substituted diarylsulfonamides as thrombin inhibitors.
- To investigate the structure-activity relationships of these compounds.
- To elucidate the binding mode of potent inhibitors within the thrombin active site.
Main Methods:
- Chemical synthesis of diarylsulfonamide derivatives.
- Enzyme inhibition assays against thrombin and related proteases (trypsin, plasmin, factor Xa).
- X-ray crystallography to determine the complex structures of thrombin with inhibitors.
Main Results:
- A series of potent thrombin inhibitors were synthesized.
- The most effective compound, N-[3-(4-guanidinobutoxy)-5-methyl-phenyl]-benzenesulfonamide (6c), exhibited a Ki of 0.18 microM for thrombin.
- Compound 6c demonstrated high selectivity, with no significant inhibition of trypsin, plasmin, or factor Xa.
- X-ray crystallography revealed detailed binding interactions of the inhibitors within the thrombin active site.
Conclusions:
- Guanidinoalkyl-substituted diarylsulfonamides represent a promising class of selective thrombin inhibitors.
- Structural insights from X-ray crystallography provide a foundation for optimizing inhibitor design.
- These findings contribute to the development of targeted anticoagulant therapies.